Official Journal of
East European Branch of
CardiOncology Society
Piotr Skalij, Piotr Tokajuk, Marek Z. Wojtukiewicz

Otrzymano/Received: 10.03.2020. Zaakceptowano/Accepted: 27.03.2020.

TAS-102 – a new option in the treatment of patients with advanced colorectal cancer after failure or intolerance to other therapies

TAS-102 – a new option in the treatment of patients with advanced colorectal cancer after failure or intolerance to other therapies OncoReview 2020; 1(37): 8-14. DOI: 10.24292/01.OR.120270320
STRESZCZENIE

Colorectal cancer is the second cause of death from malignant cancer, following lung cancer. Approximately 35–45% of patients with colorectal cancer will develop distant metastases over time. Palliative systemic treatment remains the standard for non-operative distant metastases. TAS-102 is a novel orally administered antineoplasmatic thymidine-based nucleoside analog which represents an approved option for the treatment of advanced metastatic colorectal cancer in patients who are refractory, or are not considered canditates for, currently available therapies.

ABSTRACT

Colorectal cancer is the second cause of death from malignant cancer, following lung cancer. Approximately 35–45% of patients with colorectal cancer will develop distant metastases over time. Palliative systemic treatment remains the standard for non-operative distant metastases. TAS-102 is a novel orally administered antineoplasmatic thymidine-based nucleoside analog which represents an approved option for the treatment of advanced metastatic colorectal cancer in patients who are refractory, or are not considered canditates for, currently available therapies.

POPRZEDNIE NUMERY